Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice

Diabetes

Volumn 60, Issue 4, 2011, Pages 1246-1257

  Shirakawa, Jun ^a   Fujii, Hideki ^b   Ohnuma, Kei ^c   Sato, Koichiro ^a   Ito, Yuzuru ^a   Kaji, Mitsuyo ^a   Sakamoto, Eri ^a   Koganei, Megumi ^d   Sasaki, Hajime ^d   Nagashima, Yoji ^a   Amo, Kikuko ^e   Aoki, Kazutaka ^a   Morimoto, Chikao ^c   Takeda, Eiji ^e   Terauchi, Yasuo ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d MEIJI DAIRIES CORPORATION   (Japan)

^e UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DES FLUORO SITAGLIPTIN; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FATTY ACID SYNTHASE; GLUCOKINASE; GLYCOPROTEIN P 15095; LEPTIN; LINOLEIC ACID; OLEIC ACID; PADGEM PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PLASMINOGEN ACTIVATOR INHIBITOR 1; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; SUCROSE; UNCLASSIFIED DRUG;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CD8+ T LYMPHOCYTE; CELL SIZE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIABETES MELLITUS; DIET; DRUG EFFECT; ENZYME INHIBITION; EPIDIDYMIS FAT; FATTY LIVER; HORMONE BLOOD LEVEL; INTRAABDOMINAL FAT; LIPOHYPERTROPHY; MACROPHAGE; MALE; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION;

ADIPOSE TISSUE; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; CHEMOKINE CCL2; DIETARY FATS; DIETARY SUCROSE; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FATTY LIVER; FEMALE; GLUCOKINASE; HYPERTROPHY; INSULIN; INTERFERON-GAMMA; INTERLEUKIN-10; LIVER; MALE; MICE; PEPTIDES; POLYMERASE CHAIN REACTION; TRIGLYCERIDES; TUMOR NECROSIS FACTOR-ALPHA; VENOMS;

EID: 79953213304     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db10-1338     Document Type: Article

References (48)

1. Grundy SM, Abate N, Chandalia M. Diet composition and the metabolic syndrome: what is the optimal fat intake? Am J Med 2002;113(Suppl. 9B):25S-29S
2. Poitout V, Robertson RP. Glucolipotoxicity: fuel excess and beta-cell dysfunction. Endocr Rev 2008;29:351-366 (Pubitemid 351679704)
3. Matsuzawa Y. The role of fat topology in the risk of disease. Int J Obes (Lond) 2008;32(Suppl. 7):S83-S92
4. Neels JG, Olefsky JM. Inflamed fat: what starts the fire? J Clin Invest 2006;116:33-35
5. Qureshi K, Abrams GA. Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol 2007;13:3540-3553 (Pubitemid 47162261)
6. Hodson L, Skeaff CM, Fielding BA. Fatty acid composition of adipose tissue and blood in humans and its use as a biomarker of dietary intake. Prog Lipid Res 2008;47:348-380
7. Sato K, Arai H, Mizuno A, et al. Dietary palatinose and oleic acid ameliorate disorders of glucose and lipid metabolism in Zucker fatty rats. J Nutr 2007;137:1908-1915 (Pubitemid 47292738)
8. Kim D, Wang L, Beconi M, et al. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6- dihydro[1,2,4]triazolo [4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan- 2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005;48:141-151
9. Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999;48:2270-2276 (Pubitemid 30395416)
10. Farilla L, Hui H, Bertolotto C, et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 2002;143:4397-4408 (Pubitemid 35239574)
11. Ahrén B. GLP-1 and extra-islet effects. Horm Metab Res 2004;36:842-845 (Pubitemid 40115908)
12. Verge D, López X. Impact of GLP-1 and GLP-1 receptor agonists on cardiovascular risk factors in type 2 diabetes. Curr Diabetes Rev 2010;6:191-200
13. Ding X, Saxena NK, Lin S, Gupta NA, Anania FA. Exendin-4, a glucagonlike protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 2006;43:173-181 (Pubitemid 43733604)
14. Lee YS, Shin S, Shigihara T, et al. Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis. Diabetes 2007;56:1671-1679 (Pubitemid 46842602)
15. Gupta NA, Mells J, Dunham RM, et al. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 2010;51:1584-1592
16. Arakawa M, Mita T, Azuma K, et al. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagonlike peptide-1 receptor agonist, exendin-4. Diabetes 2010;59:1030-1037
17. Hadjiyanni I, Siminovitch KA, Danska JS, Drucker DJ. Glucagon-like peptide-1 receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells. Diabetologia 2010;53:730-740
18. Terauchi Y, Sakura H, Yasuda K, et al. Pancreatic beta-cell-specific targeted disruption of glucokinase gene. Diabetes mellitus due to defective insulin secretion to glucose. J Biol Chem 1995;270:30253-30256
19. Terauchi Y, Takamoto I, Kubota N, et al. Glucokinase and IRS-2 are required for compensatory beta cell hyperplasia in response to high-fat diet-induced insulin resistance. J Clin Invest 2007;117:246-257 (Pubitemid 46048470)
20. Lamont BJ, Drucker DJ. Differential antidiabetic efficacy of incretin agonists versus DPP-4 inhibition in high fat fed mice. Diabetes 2008;57:190-198
21. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 2007;117:175-184 (Pubitemid 46048464)
22. Shirakawa J, Wang Y, Tahara-Hanaoka S, Honda S, Shibuya K, Shibuya A. LFA-1-dependent lipid raft recruitment of DNAM-1 (CD226) in CD4+ T cell. Int Immunol 2006;18:951-957 (Pubitemid 43983290)
23. Ohnuma K, Yamochi T, Uchiyama M, et al. CD26 up-regulates expression of CD86 on antigen-presenting cells by means of caveolin-1. Proc Natl Acad Sci USA 2004;101:14186-14191 (Pubitemid 39305051)
24. Cinti S, Mitchell G, Barbatelli G, et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res 2005;46:2347-2355 (Pubitemid 41532523)
25. Kishore P, Li W, Tonelli J, et al. Adipocyte-derived factors potentiate nutrient-induced production of plasminogen activator inhibitor-1 by macrophages. Sci Transl Med 2010;2:20ra15
26. Nishimura S, Manabe I, Nagasaki M, et al. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med 2009;15:914-920
27. Kintscher U, Hartge M, Hess K, et al. T-lymphocyte infiltration in visceral adipose tissue: a primary event in adipose tissue inflammation and the development of obesity-mediated insulin resistance. Arterioscler Thromb Vasc Biol 2008;28:1304-1310
28. Rausch ME, Weisberg S, Vardhana P, Tortoriello DV. Obesity in C57BL/6J mice is characterized by adipose tissue hypoxia and cytotoxic T-cell infiltration. Int J Obes (Lond) 2008;32:451-463 (Pubitemid 351414814)
29. Nishimura S, Manabe I, Nagasaki M, et al. In vivo imaging in mice reveals local cell dynamics and inflammation in obese adipose tissue. J Clin Invest 2008;118:710-721
30. Ohnuma K, Dang NH, Morimoto C. Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function. Trends Immunol 2008;29:295-301
31. Ohnuma K, Munakata Y, Ishii T, et al. Soluble CD26/dipeptidyl peptidase IV induces T cell proliferation through CD86 up-regulation on APCs. J Immunol 2001;167:6745-6755 (Pubitemid 33144164)
32. Anstee QM, Goldin RD. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol 2006;87:1-16
33. Feldstein AE, Canbay A, Guicciardi ME, Higuchi H, Bronk SF, Gores GJ. Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. J Hepatol 2003;39:978-983 (Pubitemid 37523769)
34. Eliassen KA, Brodal BP, Svindland A, et al. Activity of peroxisomal enzymes, and levels of polyamines in LPA-transgenic mice on two different diets. Lipids Health Dis 2005;4:23
35. Gustafson B, Hammarstedt A, Andersson CX, Smith U. Inflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2007;27:2276-2283 (Pubitemid 350203940)
36. Sumiyoshi M, Sakanaka M, Kimura Y. Chronic intake of high-fat and highsucrose diets differentially affects glucose intolerance in mice. J Nutr 2006;136:582-587 (Pubitemid 43363739)
37. Saraswathi V, Wu G, Toborek M, Hennig B. Linoleic acid-induced endothelial activation: role of calcium and peroxynitrite signaling. J Lipid Res 2004;45:794-804 (Pubitemid 38552849)
38. Schmitz G, Ecker J. The opposing effects of n-3 and n-6 fatty acids. Prog Lipid Res 2008;47:147-155
39. Horrillo R, González-Périz A, Martínez-Clemente M, et al. 5-lipoxygenase activating protein signals adipose tissue inflammation and lipid dysfunction in experimental obesity. J Immunol 2010;184:3978-3987
40. Hatley ME, Srinivasan S, Reilly KB, Bolick DT, Hedrick CC. Increased production of 12/15 lipoxygenase eicosanoids accelerates monocyte/endothelial interactions in diabetic db/db mice. J Biol Chem 2003;278:25369-25375 (Pubitemid 36835286)
41. Conarello SL, Li Z, Ronan J, et al. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc Natl Acad Sci USA 2003;100:6825-6830 (Pubitemid 36666664)
42. Ahrén B. Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications. Diabetes Care 2007;30:1344-1350 (Pubitemid 46871136)
43. Miyawaki K, Yamada Y, Ban N, et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 2002;8:738-742 (Pubitemid 34778728)
44. Lê KA, Tappy L. Metabolic effects of fructose. Curr Opin Clin Nutr Metab Care 2006;9:469-475 (Pubitemid 44097820)
45. Bizeau ME, Pagliassotti MJ. Hepatic adaptations to sucrose and fructose. Metabolism 2005;54:1189-1201 (Pubitemid 41206880)
46. Stanhope KL, Schwarz JM, Keim NL, et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest 2009;119:1322-1334
47. Oyadomari S, Harding HP, Zhang Y, Oyadomari M, Ron D. Dephosphorylation of translation initiation factor 2alpha enhances glucose tolerance and attenuates hepatosteatosis in mice. Cell Metab 2008;7:520-532 (Pubitemid 351729207)
48. Hsieh J, Longuet C, Baker CL, et al. The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia 2010;53:552-561